 Peter Kennealey
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 6 | 2021 | 541 | 1.120 |
Why?
| | Kidney Failure, Chronic | 4 | 2023 | 489 | 0.990 |
Why?
| | Thrombelastography | 4 | 2023 | 180 | 0.930 |
Why?
| | Tissue Plasminogen Activator | 2 | 2023 | 225 | 0.790 |
Why?
| | Organ Transplantation | 5 | 2023 | 159 | 0.780 |
Why?
| | Pancreas Transplantation | 2 | 2018 | 61 | 0.740 |
Why?
| | Blood Coagulation | 2 | 2023 | 218 | 0.670 |
Why?
| | Renal Dialysis | 3 | 2023 | 374 | 0.630 |
Why?
| | HLA Antigens | 1 | 2019 | 225 | 0.610 |
Why?
| | Carotid Arteries | 1 | 2019 | 180 | 0.610 |
Why?
| | Simulation Training | 1 | 2018 | 61 | 0.550 |
Why?
| | General Surgery | 1 | 2018 | 127 | 0.540 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 259 | 0.490 |
Why?
| | Liver Transplantation | 4 | 2023 | 707 | 0.480 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 368 | 0.460 |
Why?
| | Clinical Competence | 1 | 2018 | 893 | 0.380 |
Why?
| | Tissue and Organ Procurement | 3 | 2023 | 228 | 0.380 |
Why?
| | Graft Survival | 5 | 2018 | 446 | 0.320 |
Why?
| | Hernia, Ventral | 1 | 2009 | 18 | 0.320 |
Why?
| | Living Donors | 3 | 2021 | 270 | 0.270 |
Why?
| | Laparoscopy | 3 | 2024 | 398 | 0.240 |
Why?
| | Peritoneal Dialysis | 1 | 2024 | 84 | 0.200 |
Why?
| | Directed Tissue Donation | 1 | 2021 | 4 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 125 | 0.190 |
Why?
| | Reperfusion | 1 | 2020 | 36 | 0.180 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 40 | 0.170 |
Why?
| | Kidney Function Tests | 1 | 2020 | 140 | 0.170 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 78 | 0.170 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | Humans | 24 | 2024 | 114709 | 0.160 |
Why?
| | Prospective Studies | 4 | 2020 | 6220 | 0.160 |
Why?
| | Female | 13 | 2024 | 59523 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1796 | 0.160 |
Why?
| | Middle Aged | 7 | 2020 | 26738 | 0.160 |
Why?
| | Male | 11 | 2023 | 55609 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 197 | 0.150 |
Why?
| | Resuscitation | 1 | 2020 | 252 | 0.150 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 136 | 0.150 |
Why?
| | Family | 1 | 2021 | 589 | 0.140 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 377 | 0.140 |
Why?
| | Cattle | 1 | 2019 | 920 | 0.140 |
Why?
| | Death | 2 | 2023 | 107 | 0.130 |
Why?
| | Adult | 7 | 2021 | 30554 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2011 | 473 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2018 | 234 | 0.120 |
Why?
| | Diabetes Complications | 1 | 2016 | 211 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2024 | 12556 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2020 | 9088 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2020 | 2128 | 0.090 |
Why?
| | Polytetrafluoroethylene | 1 | 2011 | 25 | 0.090 |
Why?
| | Aged | 4 | 2020 | 19074 | 0.090 |
Why?
| | Vascular Patency | 1 | 2011 | 97 | 0.090 |
Why?
| | Protons | 1 | 2011 | 73 | 0.090 |
Why?
| | Brain Death | 1 | 2010 | 31 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3330 | 0.090 |
Why?
| | Blood Vessel Prosthesis | 1 | 2011 | 112 | 0.090 |
Why?
| | Flavonoids | 2 | 2011 | 66 | 0.090 |
Why?
| | Fibrinolysis | 2 | 2023 | 158 | 0.090 |
Why?
| | Waiting Lists | 2 | 2021 | 211 | 0.080 |
Why?
| | Piperidines | 2 | 2011 | 160 | 0.080 |
Why?
| | Internship and Residency | 1 | 2018 | 926 | 0.080 |
Why?
| | Surgical Mesh | 1 | 2009 | 40 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6347 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2011 | 699 | 0.080 |
Why?
| | Nephrectomy | 1 | 2009 | 150 | 0.070 |
Why?
| | Biocompatible Materials | 1 | 2011 | 369 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4624 | 0.070 |
Why?
| | Creatinine | 2 | 2023 | 425 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.060 |
Why?
| | Apoptosis | 3 | 2011 | 2363 | 0.060 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2006 | 43 | 0.060 |
Why?
| | Tissue Donors | 2 | 2023 | 316 | 0.060 |
Why?
| | Young Adult | 1 | 2019 | 10472 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2011 | 615 | 0.060 |
Why?
| | Catheters, Indwelling | 1 | 2024 | 79 | 0.050 |
Why?
| | Catheterization | 1 | 2024 | 159 | 0.050 |
Why?
| | Abdominal Pain | 1 | 2024 | 135 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 81 | 0.050 |
Why?
| | Organ Preservation | 1 | 2023 | 64 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2018 | 3256 | 0.050 |
Why?
| | Perfusion | 1 | 2023 | 148 | 0.050 |
Why?
| | Kidney | 1 | 2009 | 1188 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 64 | 0.050 |
Why?
| | United States | 3 | 2023 | 12186 | 0.050 |
Why?
| | Patients | 1 | 2023 | 163 | 0.050 |
Why?
| | Adolescent | 1 | 2019 | 17855 | 0.050 |
Why?
| | Altruism | 1 | 2021 | 25 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 51 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 45 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 81 | 0.040 |
Why?
| | Animals | 2 | 2019 | 31709 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 103 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 1879 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 351 | 0.040 |
Why?
| | Patient Selection | 2 | 2016 | 641 | 0.040 |
Why?
| | Survival Rate | 2 | 2016 | 1644 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 476 | 0.040 |
Why?
| | Aging | 1 | 2008 | 1618 | 0.040 |
Why?
| | Teratocarcinoma | 1 | 1995 | 2 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6116 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1768 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1320 | 0.030 |
Why?
| | Cell Cycle | 2 | 2011 | 542 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 4895 | 0.020 |
Why?
| | Choline Kinase | 1 | 2011 | 3 | 0.020 |
Why?
| | Choline-Phosphate Cytidylyltransferase | 1 | 2011 | 3 | 0.020 |
Why?
| | Phosphorus Isotopes | 1 | 2011 | 7 | 0.020 |
Why?
| | HCT116 Cells | 1 | 2011 | 70 | 0.020 |
Why?
| | Neoplasms | 1 | 2004 | 2097 | 0.020 |
Why?
| | Camptothecin | 1 | 2011 | 96 | 0.020 |
Why?
| | Angiography | 1 | 2009 | 174 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2011 | 476 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 63 | 0.020 |
Why?
| | Brain Injuries | 1 | 2010 | 461 | 0.020 |
Why?
| | Benzamides | 1 | 2006 | 169 | 0.020 |
Why?
| | Graft Rejection | 1 | 2008 | 513 | 0.020 |
Why?
| | Body Water | 1 | 2004 | 19 | 0.010 |
Why?
| | Hydrogen | 1 | 2004 | 59 | 0.010 |
Why?
| | Piperazines | 1 | 2006 | 309 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 594 | 0.010 |
Why?
| | RNA Polymerase II | 1 | 2006 | 284 | 0.010 |
Why?
| | Pyrimidines | 1 | 2006 | 376 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1356 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 850 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1569 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1131 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1313 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4411 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 2711 | 0.010 |
Why?
| | Genes, p53 | 1 | 1995 | 61 | 0.010 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 1995 | 127 | 0.010 |
Why?
| | Mice | 1 | 2011 | 14872 | 0.010 |
Why?
| | Cell Survival | 1 | 1995 | 1021 | 0.010 |
Why?
|
|
Kennealey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|